Altered biomarkers for cardiovascular disease and inflammation in autoimmune Addison's disease: a cross-sectional studyPractice for Endocrinology and Nephrology, Endocrinology in Charlottenburg, Berlin, Germany.
Department of Endocrinology, Oslo University Hospital, Oslo, Norway.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
Department of Medicine, Vestfold Hospital Trust, Tønsberg, Norway.
Department of Internal Medicine, Haugesund Hospital, Haugesund, Norway.
Department of Internal Medicine, Haugesund Hospital, Haugesund, Norway.
Department of Endocrinology, Stavanger University Hospital, Stavanger, Norway.
Department of Medicine, Sørlandet Hospital, Kristiansand, Norway.
Department of Medicine, Drammen Hospital, Vestre Viken Health Trust, Drammen, Norway.
Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.
Department of Endocrinology, Akershus University Hospital, Lørenskog, Norway.
Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway; Tromsø Endocrine Research Group, Department of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Section of Endocrinology, Innlandet Hospital Trust, Hamar, Norway.
Section of Endocrinology, Innlandet Hospital Trust, Hamar, Norway.
Department of Endocrinology, Linköping University, Linköping, 581 85, Sweden; Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Department of Medicine, Sørlandet Hospital, Arendal, Norway.
K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden; Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Department of Endocrinology, Karolinska University Hospital, Stockholm, Sweden.
Department of Clinical Science, University of Bergen, Bergen, Norway; K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Science, University of Bergen, Bergen, Norway; K.G. Jebsen Center for Autoimmune Disorders, University of Bergen, Bergen, Norway; Department of Medicine, Haukeland University Hospital, Bergen, Norway; Department of Medicine (Solna), Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
Show others and affiliations
2023 (English)In: European Journal of Endocrinology, ISSN 0804-4643, E-ISSN 1479-683X, Vol. 189, no 4, p. 438-447Article in journal (Refereed) Published
Abstract [en]
Objective: Increased prevalence of cardiovascular disease has been reported in autoimmune Addison's disease (AAD), but pathomechanisms are poorly understood.
Design: Cross-sectional study.Methods: We compared serum levels of 177 cardiovascular and inflammatory biomarkers in 43 patients with AAD at >18-h glucocorticoid withdrawal and 43 matched controls, overall and stratified for sex. Biomarker levels were correlated with the frequency of adrenal crises and quality of life (QoL) by AddiQoL-30. Finally, we investigated changes in biomarker levels following 250 µg tetracosactide injection in patients without residual adrenocortical function (RAF) to explore glucocorticoid-independent effects of high ACTH.
Results: Nineteen biomarkers significantly differed between patients with AAD and controls; all but 1 (ST1A1) were higher in AAD. Eight biomarkers were significantly higher in female patients compared with controls (IL6, MCP1, GAL9, SPON2, DR4, RAGE, TNFRSF9, and PGF), but none differed between male patients and controls. Levels of RAGE correlated with the frequency of adrenal crises (r = 0.415, P = .006) and AddiQoL-30 scores (r = -0.347, P = .028) but not after correction for multiple testing. PDL2 and leptin significantly declined 60 min after injection of ACTH in AAD without RAF (-0.15 normalized protein expression [NPX], P = .0001, and -0.25 NPX, P = .0003, respectively).
Conclusions: We show that cardiovascular and inflammatory biomarkers are altered in AAD compared with controls, particularly in women. RAGE might be a marker of disease severity in AAD, associated with more adrenal crises and reduced QoL. High ACTH reduced PDL2 and leptin levels in a glucocorticoid-independent manner but the overall effect on biomarker profiles was small.
Place, publisher, year, edition, pages
Oxford University Press, 2023. Vol. 189, no 4, p. 438-447
Keywords [en]
autoimmunity, primary adrenal insufficiency, cardiovascular disease, proteomics, biomarkers
National Category
Endocrinology and Diabetes Clinical Medicine
Identifiers
URN: urn:nbn:se:umu:diva-217965DOI: 10.1093/ejendo/lvad136ISI: 001086414300001PubMedID: 37807083Scopus ID: 2-s2.0-85180101346OAI: oai:DiVA.org:umu-217965DiVA, id: diva2:1819663
Funder
The Research Council of Norway, 288022Novo Nordisk Foundation, NNF18OC0034130Stockholm County CouncilKarolinska Institute2023-12-142023-12-142025-02-18Bibliographically approved